🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re honored that @Accellix could participate in an engaging panel on #decentralizedmanufacturing for #celltherapy during #ISCT2025 alongside an incredible lineup of industry leaders from companies including Terumo Blood and Cell Technologies, Novartis, Galapagos, and Cryoport Systems.

#TechTuesday: How does the Accellix automated flow cytometer compare to traditional flow cytometry? Learn more in our latest technical note: "Method Comparison of the Accellix Platform vs Traditional Flow Cytometry." 📩Download it here: accellix.com/technical-note…

The Accellix team came together for our annual Volunteer Day—and what a fun and fulfilling day it was! A big thank you to Second Harvest of Silicon Valley and all our team members who generously gave their time to give back and make a difference. #AccellixCares #GivingBack #VolunteerDay

A 7-month-old with the rare genetic disorder carbamoyl phosphate synthetase 1 (CPS1) deficiency has made history as the first human patient to receive a personalized #CRISPR #genetherapy tailored to his specific mutation. newscientist.com/article/248036…

🔬 #TechTuesday: Reproducibility is critical for QC assays used in T cell therapy manufacturing. Download our technical note to see the reproducibility of the Accellix Platform using two off-the-shelf QC assays accellix.com/technical-note…

Join us during #CYTO2025 for Slingshot Biosciences's commercial tutorial: June 3rd at 12:15PM. Accellix will be presenting “Evaluation of Slingshot TruCytes™ Cell Mimics on the Accellix Automated Flow Cytometry Platform for Cell Therapy Manufacturing QC”​. See you there! #Cytometry

🔬 #TechTuesday: Evaluation of Slingshot Biosciences's TruCytes™ cell mimics on the Accellix automated #flowcytometry platform for #celltherapy MFG QC. Download the poster: accellix.com/ctad-summit-20… If you are at #CYTO2025, come to the Slingshot Biosciences tutorial today at 12:15PM MT.

CAR-T cell therapy makes headway against glioblastoma. A dual-target CAR-T design (EGFR + IL13Rα2) developed by Kite, a Gilead Company collaborators at U Penn shrank tumors in 62% of patients with recurrent glioblastoma in a new trial. penntoday.upenn.edu/news/dual-targ…

Stop by booth 13 during Allogeneic Cell Therapy Summit and be sure to join us for Accellix poster presentation Wednesday June 11th between 3-4PM ET for our poster presentation “Automating flow cytometry for objective and reproducible cell therapy QC”​. See you in Boston!

🔬 #TechTuesday: Learn how automated data analysis on the Accellix platform can shorten time to results, reduce subjectivity, and minimize data interpretation errors over manual analysis for cell therapy QC. accellix.com/technical-note… #FlowCytometry #CellTherapy

❗️REMINDER: Accellix is doing a poster presentation today between 3:00-4:00PM. Join us and learn about "Automating flow cytometry for objective and reproducible cell therapy QC". x.com/accellix/statu…

🔬Tech Tuesday - Automating Flow Cytometry for Objective and Reproducible Cell Therapy QC. Download our poster from Allogeneic Cell Therapies Summit to learn how the Accellix platform standardizes and automates the cell therapy QC workflow. accellix.com/isct-2025-post…

Early phase 1b data released from Johnson & Johnson: their dual-targeting CD19/20 CAR-T #celltherapy, JNJ-4496, achieved a 100% response rate in ten patients with relapsed or refractory large B-cell lymphoma. fiercebiotech.com/biotech/jj-hai…

🔬#TechTuesday: Simplify your flow cytometry. Get results in minutes—not hours. The Accellix platform transforms complex flow cytometry into a push-button, walkaway solution that delivers actionable, multiparametric data in minutes. Watch now: vimeo.com/445143336

🔬#TechTuesday: Download this tech note to learn how the automated Accellix Platform can measure T cell transduction efficiency for CAR-T cell development accellix.com/technical-note… #CellTherapyQC #FlowCytometry #Automation #Transduction

The U.S. FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) requirement for autologous CAR-T therapies—a meaningful step toward expanding patient access. #celltherapy x.com/alliancerm/sta…

We're pleased to welcome Félix Montero-Julian, PhD as VP of Scientific Affairs at Accellix! Welcome aboard, Félix! accellix.com/news/accellix-…

🔬#TechTuesday: See how the automated Accellix platform overcomes the limitations of traditional flow cytometry in #celltherapy QC workflows. 📽️Watch this video to learn more: accellix.com/video/traditio… #FlowCytometry #Automation #CellTherapy

🔬#TechTuesday: Download our technical note to see a detailed cost comparison between the Accellix Platform and traditional flow cytometry for cell therapy manufacturing QC: accellix.com/technical-note…

🔬#TechTuesday: Download our poster to discover how automated flow cytometric data analysis can reduce time and variability compared to manual interpretation. #celltherapy #flowcytometry accellix.com/car-tcr-summit…